Skip to main content
Thursday, September 24, 2026
Media Alert Press Media Alert Press Verify a URL
Live
RedBird Clinches Deal to Become Lead Investor in PuckTaylor Tomlinson on Quitting Late Night and Staying Quiet — Until NowTaylor Tomlinson on the Messy Demise of Her Late Night Career (Exclusive Excerpt)Johnny Depp’s Comeback Rolls On in ‘Day Drinker’ Trailer With Penélope CruzBob Iger Reveals That He Wrote a Six-Page Letter to Josh D’Amaro and Left It In His DeskLinda Cardellini Admits She “Wanted” To Recreate Pamela Voorhees’ Haircut For ‘Crystal Lake’: “We Tried It For A Second”RedBird Clinches Deal to Become Lead Investor in PuckTaylor Tomlinson on Quitting Late Night and Staying Quiet — Until NowTaylor Tomlinson on the Messy Demise of Her Late Night Career (Exclusive Excerpt)Johnny Depp’s Comeback Rolls On in ‘Day Drinker’ Trailer With Penélope CruzBob Iger Reveals That He Wrote a Six-Page Letter to Josh D’Amaro and Left It In His DeskLinda Cardellini Admits She “Wanted” To Recreate Pamela Voorhees’ Haircut For ‘Crystal Lake’: “We Tried It For A Second”
Healthcare

STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit

By Meghana Keshavan STAT News

MAP Verified Summary — reported by STAT News

Kyverna Therapeutics is one step closer to launching the first cell therapy for an autoimmune disease, with new data in hand showing many patients remained off of other therapies a…

This story’s context record documents 7 observable dimensions — Origin, Attribution, Specificity, Timing, Framing, Context Change, and Information Relationships — as part of Media Alert Press’s context-documentation ledger. MAP does not score or rate this content. Read the full original story at STAT News →

Discover more from Media Alert Press

Subscribe to get the latest posts sent to your email.

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.

Powered by